Neurotype Inc. is building precision neurotechnology to address triggers in addiction care.

The company develops EEG-based biomarkers and closed-loop neurofeedback systems designed to quantify and modulate cue reactivity, a key driver of recurrent problems and relapse in addictions.

The Neurotype platform integrates:
• NeuromarkR™ — objective EEG-based assessment
• Modit-O™ — targeted neurofeedback intervention

Developed using FDA-cleared EEG hardware, Neurotype is advancing toward regulated clinical deployment.

Founded in 2019, Neurotype operates at the intersection of neurophysiology, behavioral medicine, and digital therapeutics.

Neurotype Inc.

Org chart

Teams

Offices